Inhibition by Recombinant Hirudins of Experimental Venous Thrombosis and Disseminated Intravascular Coagulation Induced by Tissue Factor in Rats

Summary Antithrombotic potency of recombinant hirudins rHV2, rHV2–Lys47 and rHV2–Arg47 was studied in a model of experimental thrombosis induced by tissue factor in the rat. Venous thrombosis was induced by i.v. injection of 25 mg/kg tissue factor followed by stasis of the inferior vena cava. In this model natural recombinant hirudins, rHV2 and rHV2–Lys47 injected 5 min before thromboplastin totally inhibited thrombosis in the same μg range as heparin or natural hirudin extracted from leeches. However, the mutant variant rHV2–Arg47 gave a maximal 60% inhibition of thrombosis. Variants rHV2–Lys47 (30 μg/kg) and rHV2–Arg47 (157 μg/kg) injected 5 min before thromboplastin prevented by 90 to 100% the drop in platelet count observed during the disseminated intravascular coagulation induced by thromboplastin injection. Recombinant hirudins were less anticoagulant than heparin as measured by an APTT on rat plasma. After rat tail transection, rHV2–Lys47 caused a 2–fold smaller prolongation of the bleeding time than an equivalent antithrombotic dose of heparin. Plasmatic elimination of rHV2–Lys47 from rat plasma after i.v. injection had a fast distribution phase with a half-life of 3 min during which 90% of injected rHV2–Lys47 was lost and was followed by a slower elimination phase. Thus recombinant hirudin rHV2–Lys47 appears as a promising potent antithrombotic agent for the prevention of thrombin-dependent venous thrombosis and disseminated intravascular coagulation

[1]  J. Fareed,et al.  Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. , 1989, Thrombosis research.

[2]  F. Markwardt,et al.  Studies on antithrombotic effects of recombinant hirudin. , 1989, Thrombosis research.

[3]  J. Chang.  The hirudin-binding site of human alpha-thrombin. Identification of lysyl residues which participate in the combining site of hirudin-thrombin complex. , 1989, The Journal of biological chemistry.

[4]  P. Lepage,et al.  Mass spectrometry analyses of recombinant hirudins (7 kDa). , 1989, Biochemistry.

[5]  A. van Dorsselaer,et al.  Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiae. , 1989, Biochemistry.

[6]  C. Roitsch,et al.  Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin. , 1989, Protein engineering.

[7]  R. Peters,et al.  Recombinant Desulphatohirudin (CGP 39393) Anticoagulant and Antithrombotic Properties In Vivo , 1989, Thrombosis and Haemostasis.

[8]  F. Markwardt,et al.  Clinico-pharmacological studies with recombinant hirudin. , 1988, Thrombosis research.

[9]  J. Fenton,et al.  Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. , 1988, Archives of biochemistry and biophysics.

[10]  J. Hofsteenge,et al.  Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. , 1988, Biochemistry.

[11]  F. Markwardt,et al.  Pharmacological survey of recombinant hirudin. , 1988, Die Pharmazie.

[12]  A. Baici,et al.  Interaction of site specific hirudin variants with α‐thrombin , 1988 .

[13]  S. Mao,et al.  Antithrombin properties of C‐terminus of hirudin using synthetic unsulfated N α‐acetyl‐hirudin45–65 , 1987, FEBS letters.

[14]  J. Chang.  The structures and proteolytic specificities of autolysed human thrombin. , 1986, The Biochemical journal.

[15]  M. Rieger,et al.  Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. , 1986, DNA.

[16]  F. Markwardt,et al.  Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. , 1986, Thrombosis research.

[17]  J. Freyssinet,et al.  The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. , 1986, The Biochemical journal.

[18]  J. Hofsteenge,et al.  Kinetics of the inhibition of thrombin by hirudin. , 1986, Biochemistry.

[19]  T. Schäfer,et al.  Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence , 1986, FEBS letters.

[20]  J. Cazenave,et al.  Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Markwardt,et al.  Assay of hirudin in plasma using a chromogenic thrombin substrate. , 1985, Thrombosis Research.

[22]  F. Markwardt,et al.  Pharmacokinetics and Anticoagulant Effect of Hirudin in Man , 1984, Thrombosis and Haemostasis.

[23]  E. Regoeczi.  Iodine-Labeled Plasma Proteins , 1984 .

[24]  Jui-Yoa Chang.  The functional domain of hirudin, a thrombin‐specific inhibitor , 1983, FEBS letters.

[25]  E. Dejana,et al.  Bleeding Time in Rats: A Comparison of Different Experimental Conditions , 1982, Thrombosis and Haemostasis.

[26]  F. Markwardt,et al.  Pharmacological Studies on the Antithrombotic Action of Hirudin in Experimental Animals , 1982, Thrombosis and Haemostasis.

[27]  G. de Gaetano,et al.  Failure of aspirin at different doses to modify experimental thrombosis in rats. , 1980, Thrombosis research.

[28]  F. Markwardt.  The comeback of hirudin--an old-established anticoagulant agent. , 1988, Folia haematologica.

[29]  C. Roitsch,et al.  Expression and Secretion in S. Cerevisiae of Biologically Active Leech Hirudin , 1988, Bio/Technology.

[30]  F. Markwardt.  [69] Hirudin as an inhibitor of thrombin , 1970 .